EAST SETAUKET, N.Y.--(BUSINESS WIRE)--March 31, 2004--OmniCorder Technologies, Inc. (OTCBB:OMCT) today announced that Mark A.
Fauci, OmniCorder Technologies' Founder, CEO and President, will present a corporate overview highlighting the company and its technology before an audience of professional investors and clinicians, researchers and business development executives from leading pharmaceutical and medical institutions at Sachs Bloomberg LLP's "Global Biotech Forum for Investing and Partnering" at 10:30 a.m. on April 1st at the Copley Fairmont in Boston.
Commenting on his upcoming presentation, Mr. Fauci said, "This international meeting gives OmniCorder the opportunity to introduce its functional medical imaging technology to life science investors and executives of leading pharmaceutical, medical and research institutions. We believe that our BioScanIR(R) System has the potential to improve the process of drug discovery, clinical studies, and therapy monitoring by providing earlier insight into the effectiveness of treatment protocols."
About The BioScanIR(R) System:
The Company's BioScanIR(R) System, which is available commercially in the U.S. and Europe, detects diseases that affect changes in blood perfusion by detecting minute changes in the pattern of infrared photon emissions over time. The detector technology used in the system, known as a Quantum Well Infrared Photodetector (QWIP), was originally developed for the Department of Defense's Ballistic Missile Defense Initiative. The Company owns an exclusive, worldwide license to use the technology for biomedical applications. OmniCorder believes that the BioScanIR(R) System will improve disease detection and disease management capabilities in many vascular and cancer medical applications. Both cancer and vascular disease are associated with abnormal blood flow in tissues and organs.
About OmniCorder Technologies, Inc.:
OmniCorder Technologies Inc., headquartered in East Setauket, New York, is a leading developer of medical imaging applications using advanced infrared focal plane arrays. OmniCorder provides imaging technology for clinicians and researchers for drug discovery, disease detection and disease management applications.
OmniCorder's mission is to improve the quality and cost-effectiveness of healthcare services and research through identifying, acquiring and adapting military and aerospace technology for biomedical applications.
The Company recently announced a $7.8 million funding which coincided with the reverse acquisition of a publicly traded company.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, the ability of the Company to develop effective new products and receive governmental approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
CCRI Corporation Malcolm McGuire, 800-828-0406 E-mail: email@example.com or
OmniCorder Technologies, Inc. Anne Marie Fields, 631-689-2649 x216